A Phase 3 interventional study of Exparel and 0.5% Bupivacaine HCl in Postoperative Pain Management, sponsored by Pacira Pharmaceuticals, Inc. Completed at 17 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-01-06.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies testing Liposomal Bupivacaine in Pain, Postoperative — 14 open to participants now, 15 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain, Postoperative.
Among the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, this one is the 38th largest by enrollment, is one of 15 that started in 2019, is one of 11 in phase 3, and was the 39th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →14 of the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Tianjin First Central Hospital · Sites in China
Ages 18–80
Texas Scottish Rite Hospital for Children · Sites in United States
Ages 13–21
Boston Children's Hospital · Sites in United States
Ages 10–17
Texas Tech University Health Sciences Center · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 16 · Phase 4 52
First in 2012; this study’s year is marked. 15 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is above the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 80 across the 93 interventional studies. Of the 61 that completed or were terminated, 41 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 93 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
25 studies in Pain, Postoperative by Pacira BioSciences, Inc.: 1 open now, 1 under way, none of them phase 3. Of 24 finished, 19 (79%) have results posted.
Among the 25 studies in Pain, Postoperative by Pacira BioSciences, Inc., this one is the 9th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2019, is one of 5 in phase 3, and was the 22nd registered.
Pacira BioSciences, Inc.’s Pain, Postoperative studies by the year they started, since 2004.
8 of the studies testing Liposomal Bupivacaine in Pain, Postoperative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06350981Phase 3Foundation for Orthopaedic Research and EducationAnalgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion | 2027-01-01 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT03737292Milton S. Hershey Medical CenterLiposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy | 2026-12 |
| NCT06271265Pacira Pharmaceuticals, IncStudy to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery | 2027-01 |
| NCT07689162Washington University School of MedicineLiposomal Bupivacaine vs Standard Bupivacaine for Post-Rhinoplasty Analgesia | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 93 studies testing Liposomal Bupivacaine in Pain, Postoperative, from their registry updates:
Among Pacira BioSciences, Inc.’s 25 in Pain, Postoperative:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective: To evaluate the pharmacokinetics (PK) of EXPAREL in pediatric subjects aged 6 to less than 17 years undergoing various types of surgeries.
Secondary Objective: To evaluate the safety of EXPAREL in pediatric subjects aged 6 to less than 17 years undergoing various types of surgeries.
This is a Phase 3, two-part, multi-center, open-label study designed to evaluate the PK and safety profile of EXPAREL in pediatric subjects aged 6 to less than 17 years when administered intraoperatively at the end of surgery via local infiltration. 90 pediatric subjects undergoing spine and/or cardiac surgeries are planned for enrollment.
Part 1 is a multicenter, randomized, open-label study in subjects aged 6 to less than 17 years undergoing spine or cardiac surgeries. There will be 2 treatment groups: Group 1 will include subjects aged 12 to less than 17 years, while Group 2 will include subjects aged 6 to less than 12 years
Part 2 is a multicenter, randomized, open-label, safety study in subjects aged 6 to less than 17 years undergoing spine or cardiac surgeries. There will be 2 treatment groups: Group 1 will include subjects aged 12 to less than 17 years, while Group 2 will include subjects aged 6 to less than 12 years.
Subjects will be screened within 30 days prior to study drug administration. During the screening visit, subjects will be assessed for past or present neurologic, cardiac, and general medical conditions that, in the opinion of the investigator, would preclude them from study participation.
Subjects will undergo their pre-planned spinal or cardiac surgeries per the institution's standard of care. On Day 1, eligible subjects will receive the study drug intraoperatively at the end of surgery via local infiltration into the surgical site. Dosing of EXPAREL will be based on body weight, with a starting dose of 4 mg/kg (maximum 266 mg).
There is no required length of stay in the hospital; subjects may be discharged based on the medical judgment of the treating physician.
A follow-up phone call will be scheduled for all subjects on Day 7. A final follow-up visit will be made on Day 30 to all subjects who would have received the study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Administration of an drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
In addition, the subject will be ineligible to receive study drug if he or she meets the following criterion during surgery:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of spine surgery.
Drug: Exparel
Single dose of bupivacaine hydrochloride (HCl) 2 mg/kg (not to exceed a maximum total dose of 175 mg) via local infiltration at the end of spine surgery.
Drug: 0.5% Bupivacaine HCl
Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of spine surgery.
Drug: Exparel
Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of cardiac surgery.
Drug: Exparel
EXPAREL 4mg/kg (maximum 266 mg)
Also known as: Liposomal bupivacaine
Bupivacaine HCl 2mg/kg
Also known as: Bupivacaine
Area Under the Plasma Concentration-versus-time Curve (AUC) 0 to Infinity
Time frame: 15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery)
Maximum Plasma Concentration (Cmax)
Time frame: 15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery)
The Apparent Terminal Elimination Half-life (t1/2el)
Time frame: 15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery)
Apparent Clearance (CL/F)
Time frame: 15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery)
Apparent Volume of Distribution (Vd/F)
Time frame: 15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery)
Area Under the Plasma Concentration-versus-time Curve (AUC) 0 to Tlast
Time frame: 15, 30, 45 min, 1-1.25h, 2-4h, 10-18h, 24-36h, 42-60h (spine surgery) or 15, 30, 45 min, 1-1.25, 15-25, 20-40, 45-55, 64-72h (cardiac surgery)
Participants were recruited between 02 April 2019 and 24 September 2019 at 15 sites in the US (both Groups).
| Milestone | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPAREL | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, Bupivacine | Group 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPAREL | Group 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL |
|---|---|---|---|---|
| Started | 31 | 30 | 6 | 30 |
| Completed | 30 | 28 | 5 | 28 |
| Not completed | 1 | 2 | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 | 1 |
| Withdrew: Study drug was not administered | 0 | 0 | 1 | 1 |
| ng*h/mL | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPAREL | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, Bupivacine | Group 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPAREL | Group 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL |
|---|---|---|---|---|
| Area Under the Plasma Concentration-versus-time Curve (AUC) 0 to Infinity | 14246.1 ± 9118.83 | 5709.4 ± 3281.74 | 11569.5 ± 7306.07 | 26164.0 ± 28038.35 |
| ng/mL | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPAREL | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, Bupivacine | Group 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPAREL | Group 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL |
|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) | 357.3 ± 125.31 | 563.6 ± 320.93 | 319.5 ± 164.76 | 447.1 ± 243.41 |
| hours | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPAREL | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, Bupivacine | Group 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPAREL | Group 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL |
|---|---|---|---|---|
| The Apparent Terminal Elimination Half-life (t1/2el) | 26.8 ± 21.26 | 8.4 ± 6.26 | 13.4 ± 4.60 | 24.9 ± 20.58 |
| Liters/hour | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPAREL | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, Bupivacine | Group 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPAREL | Group 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL |
|---|---|---|---|---|
| Apparent Clearance (CL/F) | 17.5 ± 7.47 | 20.5 ± 8.27 | 14.5 ± 2.70 | 7.4 ± 3.20 |
| Liters | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPAREL | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, Bupivacine | Group 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPAREL | Group 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL |
|---|---|---|---|---|
| Apparent Volume of Distribution (Vd/F) | 546.4 ± 269.42 | 226.8 ± 110.63 | 271.1 ± 43.58 | 216.1 ± 83.77 |
| ng*h/mL | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPAREL | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, Bupivacine | Group 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPAREL | Group 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL |
|---|---|---|---|---|
| Area Under the Plasma Concentration-versus-time Curve (AUC) 0 to Tlast | 9042.5 ± 3762.82 | 5232.9 ± 2538.37 | 10249.6 ± 5956.56 | 16776.4 ± 7935.80 |
Collected over Screening through postsurgical Day 14. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPAREL | 0/31 (0%) | 0/31 (0%) | 19/31 (61.3%) |
| Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, Bupivacaine | 0/30 (0%) | 0/30 (0%) | 22/30 (73.3%) |
| Group 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPAREL | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Group 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL | 0/29 (0%) | 2/29 (6.9%) | 9/29 (31%) |
| Event | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPAREL | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, Bupivacaine | Group 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPAREL | Group 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL |
|---|---|---|---|---|
| DyspneaRespiratory, thoracic and mediastinal disorders | 0/31 | 0/30 | 0/5 | 1/29 |
| VomitingGastrointestinal disorders | 0/31 | 0/30 | 0/5 | 1/29 |
| Wound infection fungalInfections and infestations | 0/31 | 0/30 | 0/5 | 1/29 |
| Event | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPAREL | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, Bupivacaine | Group 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPAREL | Group 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL |
|---|---|---|---|---|
| Hypoesthesia oralGastrointestinal disorders | 1/31 | 3/30 | 3/5 | 0/29 |
| Vision blurredEye disorders | 4/31 | 3/30 | 3/5 | 1/29 |
| HypotensionVascular disorders | 2/31 | 7/30 | 2/5 | 0/29 |
| PruritisSkin and subcutaneous tissue disorders | 1/31 | 2/30 | 2/5 | 0/29 |
| NauseaGastrointestinal disorders | 10/31 | 6/30 | 1/5 | 2/29 |
| ConstipationGastrointestinal disorders | 8/31 | 9/30 | 1/5 | 4/29 |
| VomitingGastrointestinal disorders | 9/31 | 5/30 | 1/5 | 4/29 |
| Muscle twitchingMusculoskeletal and connective tissue disorders | 2/31 | 8/30 | 1/5 | 1/29 |
| DiarrheaGastrointestinal disorders | 2/31 | 0/30 | 1/5 | 0/29 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 3/31 | 0/30 | 1/5 | 0/29 |
Safety population The Safety population consisted of all subjects who underwent the planned surgery and received study treatment, with analysis by actual treatment received.
| Age, Continuous(years) | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPAREL | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, Bupivacine | Group 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPAREL | Group 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL | Total |
|---|---|---|---|---|---|
| Mean | 13.8 ± 1.33 | 13.9 ± 1.33 | 10 ± 1.73 | 8.7 ± 1.77 | 12.1 ± 2.81 |
| Sex: Female, Male(Participants) | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPAREL | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, Bupivacine | Group 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPAREL | Group 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL | Total |
|---|---|---|---|---|---|
| Female | 28 | 22 | 2 | 14 | 66 |
| Male | 3 | 8 | 3 | 15 | 29 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPAREL | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, Bupivacine | Group 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPAREL | Group 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 10 | 7 | 0 | 9 | 26 |
| Not Hispanic or Latino | 19 | 23 | 5 | 20 | 67 |
| Unknown or Not Reported | 2 | 0 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPAREL | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, Bupivacine | Group 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPAREL | Group 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 0 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 5 | 3 | 1 | 2 | 11 |
| White | 21 | 26 | 4 | 26 | 77 |
| More than one race | 1 | 1 | 0 | 0 | 2 |
| Unknown or Not Reported | 2 | 0 | 0 | 0 | 2 |
| Region of Enrollment(participants) | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPAREL | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, Bupivacine | Group 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPAREL | Group 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL | Total |
|---|---|---|---|---|---|
| United States | 31 | 30 | 5 | 29 | 95 |
| American Society of Anesthesiologists classification(Participants) | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, EXPAREL | Group 1: 12 to Less Than 17 Years, Undergoing Spine Surgery, Bupivacine | Group 2: 6 to Less Than 12 Years, Undergoing Spine Surgery, EXPAREL | Group 2: 6 to Less Than 12 Years, Undergoing Cardiac Surgery, EXPAREL | Total |
|---|---|---|---|---|---|
| ASA 1 | 14 | 13 | 1 | 0 | 28 |
| ASA 2 | 16 | 13 | 2 | 2 | 33 |
| ASA 3 | 1 | 4 | 2 | 27 | 34 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2019 to primary completion in Aug 2019, 4 months.
Results were first posted in Jan 2021, 1 year 4 months after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 4 months is below that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal Bupivacaine